Pharmala Biotech Holdings Ratios and Metrics

Market cap in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 1, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Market Capitalization	15	14	8	19	4	-
Market Cap Growth	-6.50%	84.59%	-58.83%	356.35%	-	-
Enterprise Value	15	13	7	18	3	-
Last Close Price	0.14	0.14	0.09	0.22	0.05	-
PS Ratio	17.14	23.77	7.53	35.60	53.16	-
PB Ratio	7.07	5.86	3.94	13.69	2.18	-
P/TBV Ratio	36.81	20.92	61.41	-	6.24	-
EV/Sales Ratio	16.49	21.71	7.05	34.67	37.77	-
Net Debt / Equity Ratio	-0.27	-0.39	-0.21	-0.14	-0.45	-0.93
Net Debt / EBITDA Ratio	0.41	0.49	0.73	0.29	0.98	4.28
Net Debt / FCF Ratio	0.63	0.92	1.31	0.57	1.36	9.35
Asset Turnover	0.25	0.19	0.39	0.22	0.03	-
Inventory Turnover	0.28	0.15	0.62	0.65	-	-
Quick Ratio	1.02	1.06	0.69	0.41	2.13	18.28
Current Ratio	1.42	1.71	1.14	0.69	2.56	18.28
Return on Equity (ROE)	-62.20%	-98.00%	-48.95%	-47.41%	-43.21%	-
Return on Assets (ROA)	-25.53%	-39.77%	-13.58%	-17.63%	-21.48%	-
Return on Capital Employed (ROCE)	-66.70%	-81.80%	-29.10%	-48.40%	-46.20%	-21.80%
Earnings Yield	-10.71%	-15.12%	-10.56%	-4.12%	-23.75%	-
FCF Yield	-6.04%	-7.27%	-4.12%	-1.79%	-15.14%	-
Buyback Yield / Dilution	-12.44%	-12.42%	-4.79%	-5.98%	-163.82%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.